Biogen Media |

All Press Releases

SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency
7/17/16 9:05 pm EDT
Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
7/5/16 8:00 am EDT
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
6/21/16 11:00 am EDT
Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
6/20/16 4:01 pm EDT
New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
6/9/16 7:08 am EDT
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
6/7/16 7:30 am EDT
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program
6/1/16 11:45 am EDT
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
5/31/16 7:30 am EDT
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
5/30/16 2:05 am EDT
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
5/27/16 9:36 pm EDT

SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency
7/17/16 9:05 pm EDT
Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
7/5/16 8:00 am EDT
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
6/21/16 11:00 am EDT
Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
6/20/16 4:01 pm EDT
New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
6/9/16 7:08 am EDT
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
6/7/16 7:30 am EDT
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program
6/1/16 11:45 am EDT
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
5/31/16 7:30 am EDT
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union
5/30/16 2:05 am EDT
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis
5/27/16 9:36 pm EDT